Cargando…

Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer

AIMS: Compare lurbinectedin versus other second-line (2L) small-cell lung cancer (SCLC) treatments. METHODS: An unanchored matching-adjusted indirect comparison connected the platinum-sensitive SCLC cohort of a single-arm lurbinectedin trial to a network of three randomized controlled trials (oral a...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanvesakul, Raj, Rengarajan, Badri, Naveh, Navit, Boccuti, Anne, Park, Julie E, Adeyemi, Adekemi, Caisip, Clyde, Jansen, Jeroen P, Wilson, Florence R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Becaris Publishing Ltd 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10402758/
https://www.ncbi.nlm.nih.gov/pubmed/37079341
http://dx.doi.org/10.57264/cer-2022-0098
_version_ 1785084911981428736
author Hanvesakul, Raj
Rengarajan, Badri
Naveh, Navit
Boccuti, Anne
Park, Julie E
Adeyemi, Adekemi
Caisip, Clyde
Jansen, Jeroen P
Wilson, Florence R
author_facet Hanvesakul, Raj
Rengarajan, Badri
Naveh, Navit
Boccuti, Anne
Park, Julie E
Adeyemi, Adekemi
Caisip, Clyde
Jansen, Jeroen P
Wilson, Florence R
author_sort Hanvesakul, Raj
collection PubMed
description AIMS: Compare lurbinectedin versus other second-line (2L) small-cell lung cancer (SCLC) treatments. METHODS: An unanchored matching-adjusted indirect comparison connected the platinum-sensitive SCLC cohort of a single-arm lurbinectedin trial to a network of three randomized controlled trials (oral and intravenous [IV] topotecan, and platinum re-challenge) identified by systematic literature review. Network meta-analysis methods estimated relative treatment effects. RESULTS: In platinum-sensitive patients, lurbinectedin demonstrated a survival benefit and favorable safety profile versus oral and IV topotecan and platinum re-challenge (overall survival, hazard ratio [HR]: 0.43; 95% credible interval [CrI]: 0.27, 0.67; HR: 0.43; 95% CrI: 0.26, 0.70; HR: 0.42; 95% CrI: 0.30, 0.58 respectively). CONCLUSION: Lurbinectedin showed a robust survival benefit and favorable safety versus other SCLC treatments in 2L platinum-sensitive SCLC.
format Online
Article
Text
id pubmed-10402758
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Becaris Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-104027582023-08-11 Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer Hanvesakul, Raj Rengarajan, Badri Naveh, Navit Boccuti, Anne Park, Julie E Adeyemi, Adekemi Caisip, Clyde Jansen, Jeroen P Wilson, Florence R J Comp Eff Res Research Article AIMS: Compare lurbinectedin versus other second-line (2L) small-cell lung cancer (SCLC) treatments. METHODS: An unanchored matching-adjusted indirect comparison connected the platinum-sensitive SCLC cohort of a single-arm lurbinectedin trial to a network of three randomized controlled trials (oral and intravenous [IV] topotecan, and platinum re-challenge) identified by systematic literature review. Network meta-analysis methods estimated relative treatment effects. RESULTS: In platinum-sensitive patients, lurbinectedin demonstrated a survival benefit and favorable safety profile versus oral and IV topotecan and platinum re-challenge (overall survival, hazard ratio [HR]: 0.43; 95% credible interval [CrI]: 0.27, 0.67; HR: 0.43; 95% CrI: 0.26, 0.70; HR: 0.42; 95% CrI: 0.30, 0.58 respectively). CONCLUSION: Lurbinectedin showed a robust survival benefit and favorable safety versus other SCLC treatments in 2L platinum-sensitive SCLC. Becaris Publishing Ltd 2023-04-20 /pmc/articles/PMC10402758/ /pubmed/37079341 http://dx.doi.org/10.57264/cer-2022-0098 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License (https://creativecommons.org/licenses/by-nc-nd/4.0/)
spellingShingle Research Article
Hanvesakul, Raj
Rengarajan, Badri
Naveh, Navit
Boccuti, Anne
Park, Julie E
Adeyemi, Adekemi
Caisip, Clyde
Jansen, Jeroen P
Wilson, Florence R
Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer
title Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer
title_full Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer
title_fullStr Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer
title_full_unstemmed Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer
title_short Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer
title_sort indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10402758/
https://www.ncbi.nlm.nih.gov/pubmed/37079341
http://dx.doi.org/10.57264/cer-2022-0098
work_keys_str_mv AT hanvesakulraj indirecttreatmentcomparisonoflurbinectedinversusothersecondlinetreatmentsforsmallcelllungcancer
AT rengarajanbadri indirecttreatmentcomparisonoflurbinectedinversusothersecondlinetreatmentsforsmallcelllungcancer
AT navehnavit indirecttreatmentcomparisonoflurbinectedinversusothersecondlinetreatmentsforsmallcelllungcancer
AT boccutianne indirecttreatmentcomparisonoflurbinectedinversusothersecondlinetreatmentsforsmallcelllungcancer
AT parkjuliee indirecttreatmentcomparisonoflurbinectedinversusothersecondlinetreatmentsforsmallcelllungcancer
AT adeyemiadekemi indirecttreatmentcomparisonoflurbinectedinversusothersecondlinetreatmentsforsmallcelllungcancer
AT caisipclyde indirecttreatmentcomparisonoflurbinectedinversusothersecondlinetreatmentsforsmallcelllungcancer
AT jansenjeroenp indirecttreatmentcomparisonoflurbinectedinversusothersecondlinetreatmentsforsmallcelllungcancer
AT wilsonflorencer indirecttreatmentcomparisonoflurbinectedinversusothersecondlinetreatmentsforsmallcelllungcancer